Čájehuvvojit 1 - 1 oktiibuot 1 bohtosis ohcui REPOSIT study group' Sirdás sisdollui
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Aiddostahtton
  • Dahkki
  • REPOSIT study group
Čájehuvvojit 1 - 1 oktiibuot 1 bohtosis ohcui REPOSIT study group', ohcanáigi: 0,02s Aiddostahte ozu
  1. 1
    Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

    Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characterist... Dahkki Bernies van der Hiel, John B.A.G. Haanen, Marcel P.M. Stokkel, Daniel S. Peeper, Connie R. Jimenez, Jos H. Beijnen, Bart A. van de Wiel, Ronald Boellaard, Alfons J.M. van den Eertwegh, REPOSIT study group

    Almmustuhtton 2017-09-01
    Viečča ollesdeavstta
    Artihkal

Ohcanreaiddut:

  • RSS-biepmus
  • Sádde ozu šleađgaboasttain

Ozu molssaeavttut

  • Ohcanhistorjá
  • Aiddostahtton ohcu

Viečča lasi

  • Bláđe logahallama
  • Bláđe alfabehtalaš ortnegis
  • Dutkka kanálaid
  • Gursagirjjit
  • Ođatlogahallan

Dárbbašatgo veahki?

  • Ohcanráva
  • Jeara girjerájus
  • DJG:t